Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Contract Services

Apellis Pharmaceuticals to acquire Potentia Pharmaceuticals Apellis Pharmaceuticals announced that it entered into an agreement to acquire Potentia Pharmaceuticals.
Contract Research & Services > Contract Services > News
3SBio enters into license deal with PharmAbcine for Tanibirumab By PBR Staff Writer
Chinese biotechnology firm 3SBio has entered into an exclusive license with PharmAbcine to develop, manufacture and market Tanibirumab, an anti-VEGFR2/KDR antibody for cancer.
Contract Research & Services > Contract Services > News Cardiome inks commercialization deal with Aspen for Brinavess in South Africa By PBR Staff Writer
Cardiome Pharma has entered into an agreement with Pharmacare, which trades as Aspen Pharmacare, to sell and distribute Brinavess (vernakalant intravenous) in South Africa.
Contract Research & Services > Contract Services > News
See more Contract Services news

Latest Contract Services News and Insight

View all Contract Services news or find news targeted to your interests
Cardiome inks commercialization deal with Aspen for Brinavess in South Africa
By PBR Staff Writer
Cardiome Pharma has entered into an agreement with Pharmacare, which trades as Aspen Pharmacare, to sell and distribute Brinavess (vernakalant intravenous) in South Africa.
Contract Research & Services > Contract Services > News
Dicerna inks license agreement with Tekmira to advance PH1 development program
Dicerna Pharmaceuticals, a leading developer of RNA interference (RNAi) therapeutics, announced a licensing agreement for Dicerna to use Tekmira’s proprietary lipid nanoparticle (LNP) technology for delivery of DCR-PH1, Dicerna’s investigational product candidate for primary hyperoxaluria type 1 (PH1), a rare, inherited liver disorder that often results in kidney failure, and for which there are no approved therapies.
Contract Research & Services > Contract Services > News
RetroSense Therapeutics signs license deal with Massachusetts General Hospital
RetroSense Therapeutics, a privately-held biopharmaceutical company, announced the signing of a license agreement for exclusive, worldwide rights to Massachusetts General Hospital’s patent application entitled "Method for Augmenting Vision in Persons Suffering from Photoreceptor Cell Degeneration".
Contract Research & Services > Contract Services > News
Pfizer, Merck to jointly develop and commercialize new cancer treatments
By PBR Staff Writer
Pfizer has entered into an agreement with Merck to jointly develop and commercialize MSB0010718C, an investigational anti-PD-L1 antibody being developed by Merck as a potential treatment for several types of cancer.
Contract Research & Services > Contract Services > News
Inovio and Roche terminate joint development agreement for INO-5150
By PBR Staff Writer
Inovio Pharmaceuticals and Roche have terminated their collaboration, option and license deal signed in 2013 to jointly develop INO-5150, Inovio's DNA immunotherapy targeting prostate cancer, as well as their research collaboration in prostate cancer.
Contract Research & Services > Contract Services > News
Stellar, Araclon sign KLH supply deal for clinical trials in Alzheimer's active immunotherapies
By PBR Staff Writer
Stellar Biotechnologies and Araclon Biotech have signed a supply agreement to meet Araclon's Phase II and III clinical trial requirements for Keyhole Limpet Hemocyanin (KLH) used in its active immunotherapies against Alzheimer's disease (AD).
Contract Research & Services > Contract Services > News
Hybrigenics Services - Protein Interactions Expert
Who else knows your protein better than you? Who else knows proteins interactions better than us?
Contract Research & Services > Contract Services > Suppliers
Cartagenia, CollabRx partner to provide pathology laboratories and cancer centers access to personalized information on therapeutic options
Cartagenia, leader in providing genetic labs and clinicians with software-based workflow support for variant assessment, lab reporting, and access of relevant knowledge-bases, announced a partnership with CollabRx that will provide Cartagenia's customers access to CollabRx's industry-leading treatment information resources and services.
Contract Research & Services > Contract Services > News
Pharco to develop Presidio's NS5A inhibitor PPI-668 for HCV in Egypt
By PBR Staff Writer
Pharco Pharmaceuticals has entered into an exclusive license agreement to develop and commercialize Presidio’s clinical stage hepatitis C virus (HCV) NS5A inhibitor PPI-668 in Egypt.
Contract Research & Services > Contract Services > News
Advent, Avista Capital Partners to acquire Kremers Urban Pharmaceuticals from UCB
Advent International and Avista Capital Partners have signed an agreement to acquire Kremers Urban Pharmaceuticals, the US specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB, for $1.525bn.
Contract Research & Services > Contract Services > News
View all Contract Services news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250